ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT03241810

Public ClinicalTrials.gov record NCT03241810. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)

Study identification

NCT ID
NCT03241810
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Elevation Oncology
Industry
Enrollment
22 participants

Conditions and interventions

Interventions

  • Fulvestrant Drug
  • Placebo Drug
  • Seribantumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 14, 2017
Primary completion
Nov 29, 2018
Completion
Nov 29, 2018
Last update posted
Sep 1, 2020

2017 – 2018

United States locations

U.S. sites
22
U.S. states
16
U.S. cities
22
Facility City State ZIP Site status
Ironwood Cancer and Research Centers- Chandler Chandler Arizona 85224
Highland Oncology Group Fayetteville Arkansas 72703
Beverly Hills Cancer Center Beverly Hills California 90404-2131
Stanford University Palo Alto California 94304
Saint Helena Hospital St. Helena California 94574
Stamford Hospital Stamford Connecticut 06902-3628
Sylvester Comprehensive Cancer Center Miami Florida 33136
UF Health Cancer Center at Orlando Health Orlando Florida 32806
Moffitt Cancer Center Tampa Florida 33612
Columbus Regional Research Institute Columbus Georgia 31904
Cancer Care Specialists of Central Illinois Decatur Illinois 62526
James M Stockman Cancer Institute Frederick Maryland 21701
Holy Cross Hospital Health Center Silver Spring Maryland 20902
Lahey Clinical Medical Center Burlington Massachusetts 01805
University of Mississippi Jackson Mississippi 39216
Mercy Hospital Springfield Springfield Missouri 65804
Saint Francis Cancer Treatment Center Grand Island Nebraska 68803
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756
Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599
Oncology Specialists of Charlotte Charlotte North Carolina 28207
UPMC Cancer Center Pittsburgh Pennsylvania 15232
University of Utah Health Care - Huntsman Cancer Institute Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03241810, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 1, 2020 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03241810 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →